Meeder Asset Management Inc Crinetics Pharmaceuticals, Inc. Transaction History
Meeder Asset Management Inc
- $1.74 Billion
- Q3 2025
A detailed history of Meeder Asset Management Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Meeder Asset Management Inc holds 118 shares of CRNX stock, worth $5,133. This represents 0.0% of its overall portfolio holdings.
Number of Shares
118
Previous 98
20.41%
Holding current value
$5,133
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CRNX
# of Institutions
238Shares Held
90.3MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$403 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$278 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$271 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$253 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$243 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.34B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...